Urinary tartaric acid as a biomarker of wine consumption and cardiovascular risk: the PREDIMED trial
Authors' conclusion
Light-to-moderate wine consumption, measured through an objective biomarker (tartaric acid), was prospectively associated with lower CVD rate in a Mediterranean population at high cardiovascular risk.
Study context
- Population
- Mediterranean population at high cardiovascular risk (PREDIMED trial)685 cardiovascular disease (CVD) cases
- Participants
- 1,232 participants
- Exposure
- Urinary tartaric acid excretion categories
- Outcome
- Composite clinical CVD event
Methodological detailsweighted Cox regression
- Weighted Cox regression
Main finding
As reported in the abstract
CVD
Hazard ratio (95% CI)P value
3-12 μg/mL
0.62(0.38–1.00)
P = 0.05012-35 μg/mL
0.50(0.27–0.95)
P = 0.035Observational data: associations, not effects.
Further findings
Correlation of tartaric acid with self-reported wine consumption · baseline
- R
- 0.46 (95% CI 0.41; 0.50)
Self-reported wine consumption and CVD risk
- Less significant associations between self-reported wine consumption and CVD risk
Original publication
Urinary tartaric acid as a biomarker of wine consumption and cardiovascular risk: the PREDIMED trial. Eur Heart J. Published 18 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →